

# Kristina Nilsson Ekdahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12066374/publications.pdf>

Version: 2024-02-01

49  
papers

3,826  
citations

159585

30  
h-index

206112

48  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4186  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. <i>Nature Immunology</i> , 2022, 23, 861-864.	14.5	7
2	Complement activation in individuals with previous subclinical Lyme borreliosis and patients with previous Lyme neuroborreliosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 855-862.	2.9	1
3	Poly(2-aminoethyl methacrylate)-based polyampholyte brush surface with carboxylic groups to improve blood compatibility. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2020, 31, 679-693.	3.5	4
4	Animal-Free Human Whole Blood Sepsis Model to Study Changes in Innate Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 571992.	4.8	14
5	Potential of Cell Surface Engineering with Biocompatible Polymers for Biomedical Applications. <i>Langmuir</i> , 2020, 36, 12088-12106.	3.5	14
6	Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1720-1724.	3.4	63
7	Properdin binding to complement activating surfaces depends on initial C3b deposition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E534-E539.	7.1	69
8	Absence of conformational change in complement factor 3 and factor XII adsorbed to acrylate polymers is related to a high degree of polymer backbone flexibility. <i>Biointerphases</i> , 2017, 12, 02D417.	1.6	14
9	Dispersion of TiO <sub>2</sub> nanoparticles improves burn wound healing and tissue regeneration through specific interaction with blood serum proteins. <i>Scientific Reports</i> , 2017, 7, 15448.	3.3	75
10	Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0122048.	2.5	52
11	Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, R206.	3.5	19
12	The tick-over theory revisited: Is C3 a contact-activated protein?. <i>Immunobiology</i> , 2012, 217, 1106-1110.	1.9	121
13	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. <i>Journal of Immunology</i> , 2011, 186, 4269-4277.	0.8	85
14	Mapping pro- and antiangiogenic factors on the surface of prostasomes of normal and malignant cell origin. <i>Prostate</i> , 2010, 70, 834-847.	2.3	6
15	Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. <i>Trends in Immunology</i> , 2010, 31, 32-38.	6.8	119
16	Activated human platelets induce factor XIIIa-mediated contact activation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 11-17.	2.1	50
17	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. <i>PLoS ONE</i> , 2010, 5, e12889.	2.5	42
18	Hirudin versus heparin for use in whole blood <i>in vitro</i> biocompatibility models. <i>Journal of Biomedical Materials Research - Part A</i> , 2009, 89A, 951-959.	4.0	52

#	ARTICLE	IF	CITATIONS
19	Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. <i>Biomaterials</i> , 2009, 30, 6573-6580.	11.4	35
20	Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects. <i>Journal of Immunology</i> , 2009, 183, 6724-6732.	0.8	37
21	Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. <i>Xenotransplantation</i> , 2008, 15, 225-234.	2.8	121
22	Prothrombotic Effects of Prostatasomes Isolated from Prostatic Cancer Cell Lines and Seminal Plasma. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 080-086.	2.7	10
23	Complement and coagulation: strangers or partners in crime?. <i>Trends in Immunology</i> , 2007, 28, 184-192.	6.8	533
24	The role of complement in biomaterial-induced inflammation. <i>Molecular Immunology</i> , 2007, 44, 82-94.	2.2	384
25	Prothrombotic effect of prostatasomes of metastatic cell and seminal origin. <i>Prostate</i> , 2007, 67, 378-388.	2.3	13
26	Complement activation in Lyme neuroborreliosis – Increased levels of C1q and C3a in cerebrospinal fluid indicate complement activation in the CNS. <i>Journal of Neuroimmunology</i> , 2007, 183, 200-207.	2.3	23
27	Overexpression of ecto-protein kinases in prostatasomes of metastatic cell origin. <i>Prostate</i> , 2006, 66, 675-686.	2.3	30
28	Surface-attached PEO in the form of activated pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. <i>Journal of Biomedical Materials Research - Part A</i> , 2006, 76A, 25-34.	4.0	33
29	Possible Immunoprotective and Angiogenesis-Promoting Roles for Malignant Cell-Derived Prostatasomes: A New Paradigm for Prostatic Cancer?. , 2006, 586, 107-119.		7
30	Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. <i>Biomaterials</i> , 2005, 26, 1477-1485.	11.4	171
31	Material-specific thrombin generation following contact between metal surfaces and whole blood. <i>Biomaterials</i> , 2005, 26, 1397-1403.	11.4	69
32	Transfer of functional prostatosomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. <i>Prostate</i> , 2005, 62, 105-114.	2.3	45
33	Tissue Factor Produced by the Endocrine Cells of the Islets of Langerhans Is Associated With a Negative Outcome of Clinical Islet Transplantation. <i>Diabetes</i> , 2005, 54, 1755-1762.	0.6	294
34	Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. <i>Journal of Biomedical Materials Research Part B</i> , 2003, 67A, 458-466.	3.1	83
35	C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase. <i>Journal of Immunology</i> , 2002, 168, 5786-5791.	0.8	135
36	Inhibition of Thrombin Abrogates the Instant Blood-Mediated Inflammatory Reaction Triggered by Isolated Human Islets: Possible Application of the Thrombin Inhibitor Melagatran in Clinical Islet Transplantation. <i>Diabetes</i> , 2002, 51, 1779-1784.	0.6	242

#	ARTICLE	IF	CITATIONS
37	Complement C3b interactions studied with surface plasmon resonance technique. <i>International Immunopharmacology</i> , 2001, 1, 495-506.	3.8	49
38	Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. <i>Biomaterials</i> , 2001, 22, 2435-2443.	11.4	57
39	Contact between a polymer and whole blood: Sequence of events leading to thrombin generation. <i>Translational Research</i> , 2001, 138, 139-145.	2.3	53
40	Titanium Is a Highly Thrombogenic Biomaterial: Possible Implications for Osteogenesis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 58-64.	3.4	165
41	A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. <i>Biomaterials</i> , 1999, 20, 603-611.	11.4	118
42	Phosphorylation of Coagulation Factor XI by a Casein Kinase Released by Activated Human Platelets Increases Its Susceptibility to Activation by Factor XIIa and Thrombin. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1283-1288.	3.4	13
43	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. <i>Blood</i> , 1998, 92, 1661-1667.	1.4	133
44	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. <i>Blood</i> , 1998, 92, 1661-1667.	1.4	6
45	Phosphorylation of complement component C3 after synthesis in U937 cells by a putative protein kinase, casein kinase 2, which is regulated by CD11b: evidence that membrane-bound proteases preferentially cleave phosphorylated C3. <i>Biochemical Journal</i> , 1997, 328, 625-633.	3.7	28
46	Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus. Covariation with platelet activation and possible association with thrombosis. <i>Arthritis and Rheumatism</i> , 1997, 40, 2178-2186.	6.7	28
47	Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. <i>Journal of Clinical Immunology</i> , 1996, 16, 222-229.	3.8	68
48	Complement Activation on Radio Frequency Plasma Modified Polystyrene Surfaces. <i>Journal of Colloid and Interface Science</i> , 1993, 158, 121-128.	9.4	27
49	Development of an Immunoassay for the Detection of Minute Amounts of IgG-Coated Erythrocytes in Whole Blood and Its Application for the Assessment of Fc-Mediated Clearance of Anti-CD-Coated Erythrocytes in vivo. <i>Vox Sanguinis</i> , 1989, 57, 188-192.	1.5	9